Literature DB >> 23049343

Immunoglobulin: production, mechanisms of action and formulations.

Marcia Cristina Zago Novaretti1, Carla Luana Dinardo.   

Abstract

Human immunoglobulin (Ig) began to be applied in the clinical practice with the treatment of primary immunodeficiencies. Quickly, applications of Ig increased, as its anti-inflammatory and immunomodulatory functions were elucidated. Currently, Ig is the most commonly used blood product. Ig is obtained by processing plasma; methods, in particular, techniques to reduce plasma viral loads have been evolving over the years and include: pasteurization, solvent/ detergent treatment, caprylic acid treatment and nanofiltration. These methods contribute to increased safety and quality of blood products. The mechanisms of action of Ig not only involve the blockade of Fc receptors of phagocytes, but also control complement pathways, idiotype-anti-idiotype dimer formation, blockage of superantigen binding to T cells, inhibition of dendritic cells and stimulation of regulatory T cells (Tregs). There are several formulations of Ig available, each one with its own peculiar characteristics. In Brazil, there is stringent legislation regulating the quality of Ig. Only Ig products that completely fulfill the quality control criteria are released for use. These standards involve different tests from visual inspection to determination of anti-complementary activity. This paper will further review the history and current status of Ig, including its production and mechanisms of action. The formulations available in Brazil and also the criteria of quality control currently applied will be presented.

Entities:  

Keywords:  Antibodies; Hemoderivate drugs; Immune system; Immunoglobulins; Immunoglobulins, intravenous/ pharmacokinetics; Immunoglobulins, intravenous/therapeutic use; Plasma

Year:  2011        PMID: 23049343      PMCID: PMC3415776          DOI: 10.5581/1516-8484.20110102

Source DB:  PubMed          Journal:  Rev Bras Hematol Hemoter        ISSN: 1516-8484


  21 in total

Review 1.  Natural regulatory T cells: mechanisms of suppression.

Authors:  Makoto Miyara; Shimon Sakaguchi
Journal:  Trends Mol Med       Date:  2007-01-24       Impact factor: 11.951

Review 2.  [Latex allergy].

Authors:  M A Navarrete; A Salas; L Palacios; J F Marín; J Quiralte; J F Florido
Journal:  Farm Hosp       Date:  2006 May-Jun

3.  A new liquid intravenous immunoglobulin with three dedicated virus reduction steps: virus and prion reduction capacity.

Authors:  G Poelsler; A Berting; J Kindermann; M Spruth; T Hämmerle; W Teschner; H P Schwarz; T R Kreil
Journal:  Vox Sang       Date:  2007-12-19       Impact factor: 2.144

4.  BLOOD PROTEINS AND THEIR THERAPEUTIC VALUE.

Authors:  E J Cohn
Journal:  Science       Date:  1945-01-19       Impact factor: 47.728

5.  Critical decisions in selecting an intravenous immunoglobulin product.

Authors:  Erwin W Gelfand
Journal:  J Infus Nurs       Date:  2005 Nov-Dec

Review 6.  Purification of intravenous immunoglobulin G from human plasma--aspects of yield and virus safety.

Authors:  Andrea Buchacher; Günter Iberer
Journal:  Biotechnol J       Date:  2006-02       Impact factor: 4.677

7.  Non-A, non-B hepatitis from intravenous immunoglobulin.

Authors:  R S Lane
Journal:  Lancet       Date:  1983-10-22       Impact factor: 79.321

8.  The product: All intravenous immunoglobulins are not equivalent.

Authors:  Jerry Siegel
Journal:  Pharmacotherapy       Date:  2005-11       Impact factor: 4.705

Review 9.  New insight into the mechanism of action of IVIg: the role of dendritic cells.

Authors:  A R Crow; D Brinc; A H Lazarus
Journal:  J Thromb Haemost       Date:  2009-07       Impact factor: 5.824

10.  Robustness of solvent/detergent treatment of plasma derivatives: a data collection from Plasma Protein Therapeutics Association member companies.

Authors:  Herbert O Dichtelmüller; Lothar Biesert; Fabrizio Fabbrizzi; Rodrigo Gajardo; Albrecht Gröner; Ilka von Hoegen; Juan I Jorquera; Christoph Kempf; Thomas R Kreil; Dominique Pifat; Wendy Osheroff; Gerhard Poelsler
Journal:  Transfusion       Date:  2009-05-20       Impact factor: 3.157

View more
  3 in total

1.  Design and Evaluation of the Highly Concentrated Human IgG Formulation Using Cyclodextrin Polypseudorotaxane Hydrogels.

Authors:  Taishi Higashi; Anna Tajima; Naoko Ohshita; Tatsunori Hirotsu; Irhan Ibrahim Abu Hashim; Keiichi Motoyama; Sawako Koyama; Ruriko Iibuchi; Shiuhei Mieda; Kenji Handa; Tomoaki Kimoto; Hidetoshi Arima
Journal:  AAPS PharmSciTech       Date:  2015-03-17       Impact factor: 3.246

2.  Comparative In Vitro Immune Stimulation Analysis of Primary Human B Cells and B Cell Lines.

Authors:  Kristien Van Belle; Jean Herman; Louis Boon; Mark Waer; Ben Sprangers; Thierry Louat
Journal:  J Immunol Res       Date:  2016-12-26       Impact factor: 4.818

Review 3.  Polyvalent Immunoglobulin as a Potential Treatment Option for Patients with Recurrent COPD Exacerbations.

Authors:  Dana Unninayar; Sara J Abdallah; D William Cameron; Juthaporn Cowan
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2021-03-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.